Brief: Vir Biotechnology Successfully Initiates All Trials In Eclipse Registrational Program
06/08/2025 13:42
Aug 6 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY SUCCESSFULLY INITIATES ALL TRIALS IN ECLIPSE REGISTRATIONAL PROGRAM FOR CHRONIC HEPATITIS DELTA Source text: ID:nBw6dTWdQa Further company coverage: VIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO